全文获取类型
收费全文 | 28206篇 |
免费 | 2219篇 |
国内免费 | 1289篇 |
专业分类
耳鼻咽喉 | 507篇 |
儿科学 | 257篇 |
妇产科学 | 371篇 |
基础医学 | 1722篇 |
口腔科学 | 196篇 |
临床医学 | 2384篇 |
内科学 | 4459篇 |
皮肤病学 | 190篇 |
神经病学 | 487篇 |
特种医学 | 1616篇 |
外国民族医学 | 43篇 |
外科学 | 3974篇 |
综合类 | 5472篇 |
预防医学 | 657篇 |
眼科学 | 74篇 |
药学 | 1069篇 |
4篇 | |
中国医学 | 242篇 |
肿瘤学 | 7990篇 |
出版年
2024年 | 7篇 |
2023年 | 336篇 |
2022年 | 451篇 |
2021年 | 849篇 |
2020年 | 915篇 |
2019年 | 740篇 |
2018年 | 675篇 |
2017年 | 821篇 |
2016年 | 1037篇 |
2015年 | 894篇 |
2014年 | 1647篇 |
2013年 | 1373篇 |
2012年 | 1489篇 |
2011年 | 1701篇 |
2010年 | 1458篇 |
2009年 | 1594篇 |
2008年 | 1617篇 |
2007年 | 1854篇 |
2006年 | 1798篇 |
2005年 | 1532篇 |
2004年 | 1361篇 |
2003年 | 1160篇 |
2002年 | 1033篇 |
2001年 | 998篇 |
2000年 | 794篇 |
1999年 | 574篇 |
1998年 | 481篇 |
1997年 | 422篇 |
1996年 | 303篇 |
1995年 | 296篇 |
1994年 | 278篇 |
1993年 | 175篇 |
1992年 | 168篇 |
1991年 | 175篇 |
1990年 | 115篇 |
1989年 | 85篇 |
1988年 | 69篇 |
1987年 | 66篇 |
1986年 | 67篇 |
1985年 | 68篇 |
1984年 | 39篇 |
1983年 | 31篇 |
1982年 | 45篇 |
1981年 | 27篇 |
1980年 | 30篇 |
1979年 | 23篇 |
1978年 | 13篇 |
1977年 | 15篇 |
1976年 | 7篇 |
1975年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的探讨通过下食管括约肌(lower esophageal sphincter,LES)扩张建立咽喉反流性疾病(laryngophyngeal reflux disease,LPRD)模型的可行性。方法18只新西兰白兔随机分为实验组10只和对照组8只,对实验组动物进行LES测压定位后,使用球囊对LES进行注水扩张,对照组同法置入球囊,但不进行球囊注水。扩张前1周及扩张后2周行咽喉及食管下段pH监测,LES平均静息压检测;扩张前1周、扩张后2周及8周行喉镜检查,进行喉镜下反流体征评分;扩张后8周处死动物,对其喉部及食管下段黏膜取材,光镜下观察其病理变化。结果扩张后pH监测验证实验组造模成功8只(80.0%,8/10),实验组扩张前咽喉酸反流时间百分比(%)、反流事件数(次)、反流最长时间(s)分别为0(0,0)、0(0,0)、0(0,0),扩张后分别为17.5(8.2,29.4)、3(1,5.5)、17.2(10.2,30.8),较扩张前增加,差异有统计学意义(P<0.01)。实验组扩张前食管下段pH监测酸反流时间百分比、反流事件数、反流最长时间分别为0(0,0.7)、0(0,1)、0(0,1.2),扩张后分别为23.1(4.8,49.5)、3(1,6)、25.9(11.5,56.8),较扩张前增加,差异有统计学意义(P<0.01)。实验组扩张前LES压力28.0±5.6 mmHg,较扩张后(17.2±3.3 mmHg)升高,差异有统计学差异(P=0.001);实验组扩张前RFS评分3.1±1.2分,扩张后2周为3.6±1.4分,扩张后8周为8.6±2.5分,扩张前和扩张后2周差异无统计学意义(P=0.482),但扩张前与扩张后8周差异有统计学意义(P=0.005)。病理检查示实验组喉部及食管黏膜均可观察到不同程度慢性炎症。结论食管下括约肌球囊扩张可安全、有效地建立LPRD动物模型。 相似文献
2.
3.
目的 通过实验探讨慢病毒转染调控FoxM1表达对人肝内胆管细胞癌(ICC)增殖、侵袭能力及基质金属蛋白酶(MMP)-9和MMP-2表达的影响。方法 Western blot检测ICC细胞株HCCC-9810、RBE及SSP-25的FoxM1蛋白表达水平,选取表达量较低者作为上调FoxM1细胞株,较高者作为下调细胞株;将分别携带FoxM1质粒和shRNA的慢病毒载体转染目标上调和下调ICC细胞株,建立稳定上下调FoxM1的细胞株(Western blot验证);MTT法检测转染后细胞增殖力,Transwell侵袭实验检测细胞侵袭能力;qPCR检测各组稳定转染细胞株MMP-9及MMP-2 mRNA表达水平。结果 SSP-25的FoxM1蛋白表达最高,HCCC-9810最低,由此选取SSP-25作为下调FoxM1表达目标细胞株,HCCC-9810作为上调FoxM1表达目标细胞株。慢病毒转染成功构建稳定上调(HCCC-9810-FoxM1组)及下调FoxM1细胞株(SSP-25-shFoxM1组);HCCC-9810-FoxM1组增殖及侵袭能力明显高于HCCC-9810-Control组(均P<0.05),而SSP-25-shFoxM1组增殖及侵袭能力较SSP-25-Control组明显下降(均P<0.05);HCCC-9810-FoxM1组中MMP-9及MMP-2 mRNA表达较HCCC-9810-Control组明显升高,而SSP-25-shFoxM1组中MMP-9及MMP-2 mRNA表达较SSP-25-Control组明显降低(均P<0.01)。结论 FoxM1促进ICC细胞增殖及侵袭,可能调控MMP-9及MMP-2表达,也有可能作为ICC潜在的生物标志物。 相似文献
4.
5.
目的:探讨miRNA调控食管癌细胞CaES-17的凋亡和增殖的潜在机制。方法:纳入2019年06月至2020年06月在我院接受治疗的食管癌患者6例,采集其食管癌组织和癌旁组织后抽取总RNA进行miRNA高通量测序。在食管癌细胞CaES-17中过表达食管癌组织和癌旁组织中的差异miRNA,检测食管癌细胞CaES-17的凋亡和增殖情况。通过TargentScan7.2在线分析和荧光素酶报告实验分析miRNA的靶标mRNA。结果:6例患者的食管癌组织和癌旁组织通过高通量测序发现hsa-miR-30d-5p、hsa-miR-6818-5p、hsa-miR-525-5p、hsa-miR-1909-3p、hsa-miR-212-5p、hsa-miR-586、hsa-miR-1286、hsa-miR-365b-3p、hsa-miR-30e-5p、hsa-miR-4317在食管癌组织和癌旁组织中的表达差异在8倍以上,并且食管癌组织均高于癌旁组织。干扰上述miRNA后,发现干扰miR-586能够抑制食管癌细胞CaES-17的增殖水平和迁移水平,提高凋亡水平。过表达miR-586后,食管癌细胞CaES-17的凋亡水平下降,增殖水平和迁移水平上升。TargentScan7.2在线分析和荧光素酶报告实验发现miR-586靶向TLR7的3' 端非编码区。敲低TLR7后,食管癌细胞CaES-17的凋亡水平下降,增殖水平和迁移水平上升。过表达TLR7后,食管癌细胞CaES-17的凋亡水平上升,增殖水平和迁移水平下降。但是,同时干扰miR-586和敲低TLR7后,相比于对照食管癌细胞,食管癌细胞CaES-17的凋亡水平和增殖水平无显著差异。结论:miR-586通过靶向TLR7的3' 端非编码区,降解了TLR7的mRNA,抑制了TLR7的蛋白翻译,最终抑制了食管癌细胞CaES-17的凋亡、促进了食管癌细胞CaES-17的增殖。 相似文献
6.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2022,34(9):554-560
AimsThe Short Course Oncology Treatment (SCOT) trial indicated that 3 months of adjuvant doublet chemotherapy was non-inferior to 6 months of treatment for patients with colorectal cancer, with considerably less toxicity. The SCOT trial results were disseminated in June 2017. The aim of this study was to understand if SCOT trial findings were implemented in Scotland.Materials and methodsA retrospective analysis was carried out on a dataset derived from a source population of 5.4 million people. Eligible patients were those with stage II or III colorectal cancer who received adjuvant chemotherapy. Logistic regression was applied to understand the extent of practice change to a 3-month adjuvant chemotherapy duration after the SCOT trial results were disseminated. Interrupted time series analysis was used to visualise differences in prescribing trends before and after June 2017 for the overall cohort, and by SCOT trial eligibility.ResultsIn total, 2310 patients were included in the study; 1957 and 353 treated pre- and post-June 2017, respectively. The median treatment duration decreased from 21 weeks (interquartile range 14–24) prior to June 2017 to 12 weeks (interquartile range 12–21 weeks) after June 2017 (P < 0.001). The proportion of patients receiving over 3 months of adjuvant treatment decreased from 75% to 42% (P < 0.001). This change was most noticeable for patients who met the SCOT trial eligibility criteria, and specifically for those with low-risk stage III disease and those treated with capecitabine and oxaliplatin (CAPOX). Although practice change occurred in all locations, there were differences between regions that could be explained by pre-SCOT trial prescribing trends.DiscussionA significant change in chemotherapy prescribing occurred after dissemination of the SCOT trial results. National, real-world data can be used to capture the extent of implementation of clinical trial results. In this case, implementation was aligned with clinical trial subgroup findings. This type of analysis could be conducted to evaluate the impact of other clinical trials. 相似文献
7.
目的 探讨长链非编码RNA(lncRNA)OPA相互作用蛋白5反义转录本1(OIP5-AS1)对脑胶质瘤细胞增殖、凋亡、迁移和侵袭的影响机制。方法 收集33例胶质瘤患者(低级别胶质瘤14例、高级别胶质瘤19例)和33例颅脑损伤患者的组织标本。实时荧光定量PCR(qPCR)检测组织和细胞中OIP5-AS1、微小RNA-942-5p(miR-942-5p)和检查点激酶1(CHEK1)mRNA表达,分析胶质瘤组织中OIP5-AS1、miR-942-5p和CHEK1 mRNA表达水平的相关性。体外培养人脑胶质瘤细胞系U87、SHG-44、U251、H4和正常人星形胶质细胞NHA,Western blot检测细胞中CHEK1蛋白表达。将U87细胞分为对照(NC)组、siRNA阴性对照(si-NC)组、OIP5-AS1 siRNA(si-OIP5-AS1)组、si-OIP5-AS1+inhibitor阴性对照(si-OIP5-AS1+anti-NC)组、si-OIP5-AS1+miR-942-5p抑制剂(si-OIP5-AS1+anti-miR-942-5p)组,采用Lipofectamine 3000试剂进行转染。转染后,qPCR和Western blot检测细胞中OIP5-AS1、miR-942-5p和CHEK1 mRNA和蛋白表达水平;MTT法测定细胞增殖活性;流式细胞术检测细胞凋亡;Transwell实验检测细胞迁移和侵袭能力。最后通过双荧光素酶和RNA免疫沉淀(RIP)实验验证OIP5-AS1和miR-942-5p以及CHEK1和miR-942-5p的相互作用。结果 OIP5-AS1和CHEK1在脑胶质瘤组织和细胞中过表达,miR-942-5p呈低表达(均P<0.05);相关分析显示,脑胶质瘤组织中OIP5-AS1与miR-942-5p的表达水平呈负相关,miR-942-5p与CHEK1 mRNA的表达水平呈负相关,CHEK1与OIP5-AS1 mRNA的表达水平呈正相关;且OIP5-AS1、CHEK1 mRNA在高级别胶质瘤组织中的表达明显高于低级别组织,而高级别胶质瘤中的miR-942-5p水平明显低于低级别组织(P<0.01)。沉默OIP5-AS1可显著上调miR-942-5p,抑制CHEK1的mRNA和蛋白表达(均P<0.05);沉默OIP5-AS1可显著抑制U87细胞增殖、迁移和侵袭,促进U87细胞凋亡(均P<0.05);下调miR-942-5p可上调CHEK1表达,阻断OIP5-AS1沉默对脑胶质瘤细胞生物学行为的影响(均P<0.05)。双荧光素酶和RIP实验证实miR-942-5p是OIP5-AS1的靶基因,CHEK1是miR-942-5p的下游靶基因。结论 沉默OIP5-AS1可能通过上调miR-942-5p抑制CHEK1表达,抑制脑胶质瘤细胞的侵袭和迁移,并促进细胞凋亡。 相似文献
8.
中国抗癌协会神经内分泌肿瘤专业委员会 《中国癌症杂志》2022,32(6):545-579
神经内分泌肿瘤(neuroendocrine neoplasm,NEN)是一类起源于肽能神经元和神经内分泌细胞,具有神经内分泌分化并表达神经内分泌标志物的少见肿瘤,可发生于全身各处,以肺及胃肠胰NEN(gastroenteropancreatic neuroendocrine neoplasm, GEP-NEN)最常见。国内外研究数据均提示,NEN的发病率在不断上升。美国流行病学调查结果显示,与其他类型肿瘤相比,NEN的发病率上升趋势更为显著。中国抗癌协会神经内分泌肿瘤专委会在现有循证医学证据基础上,结合已有国内外指南和共识,制订了首版中国抗癌协会神经内分泌肿瘤诊治指南,为临床工作者提供参考。 相似文献
9.
《Cancer radiothérapie》2022,26(8):1034-1044
PurposeAssess the feasibility of a randomized controlled trial (RCT) exploring the use of medical imaging as a therapeutic education (TPE) intervention in external radiation therapy.Materials and methodsExperimental feasibility trial of “RCT” type carried out in a single-center, between November 2019 and March 2020, following adult patients treated by thoracic radiotherapy. In addition to the information usually given, the experimental group benefited from an intervention consisting in the visualization of their own medical images using the open-source software “Stone of Orthanc”.ResultsForty-nine patients were recruited with a refusal rate of 8.16% (4/49). 20 patients were withdrawn from the study for health reasons (COVID), 10 for medical reasons. All the remaining 15 participants completed the process. Although not significant, the experimental group showed a median gain in the perception of knowledge compared to the control group (+ 1.9 (1.6 – 2.2)) vs (+ 1.4 (1.4 – 1.8)), as well as a decrease in scores related to anxiety (? 3.0 (?4.5 - (?2.0)) vs ? 1.0 (?5.0 - 0.0)) and emotional distress ((? 5.0 (? 7.5 - (? 3.5)) vs (? 2.0 (? 5.0 - (? 1.0)) A significant reduction (p = 0.043) is observed for the depression score ((? 2.0 (?3.0 - (?1.5)) vs (0.0 (0.0 – 0.0)).ConclusionThis study demonstrates the feasibility of the project, with promising preliminary results. Some adaptations in order to conduct a larger-scale RCT are highlighted. 相似文献
10.
Ali Soroush Reza Malekzadeh Gholamreza Roshandel Masoud Khoshnia Hossein Poustchi Farin Kamangar Paul Brennan Paolo Boffetta Sanford M. Dawsey Christian C. Abnet Julian A. Abrams Arash Etemadi 《International journal of cancer. Journal international du cancer》2023,152(6):1137-1149
Prior studies have conflicting findings regarding the association between gastroesophageal reflux disease (GERD) and esophageal squamous cell carcinoma (ESCC). We examined this relationship in a prospective cohort in a region of high ESCC incidence. Baseline exposure data were collected from 50 045 individuals using in-person interviews at the time of cohort entry. Participants were followed until they developed cancer, died, or were lost to follow up. Participants with GERD symptoms were categorized into any GERD (heartburn or regurgitation), mixed symptoms, or heartburn alone. Multivariable Cox regression was used to assess the relationship between GERD symptom group and histologically confirmed ESCC. The model was adjusted for known risk factors for GERD and ESCC. 49 559 individuals were included in this study, of which 9005 had GERD symptoms. Over 13.0 years of median follow up, 290 individuals were diagnosed with ESCC. We found no association between any GERD and risk of ESCC (aHR 0.90, 95% CI: 0.66-1.24, P = .54). Similar findings were observed for the GERD symptom subtypes. Significant interactions between any GERD and sex (P = .013) as well as tobacco smoking (P = .028) were observed. In post-hoc analyses, GERD was associated with a decreased risk of ESCC in men (aHR 0.51, 95% CI: 0.27-0.98 P = .04) and in smokers (aHR 0.26, 95% CI: 0.08-0.83 P = .02). While there was little evidence for an overall association between GERD symptoms and ESCC risk, significant interactions with sex and smoking were observed. Men and smokers with GERD symptoms had a lower risk of ESCC development. 相似文献